Matinas Biopharma (NYSEAMERICAN:MTNB) Stock Price Up 22% – Still a Buy?

Shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) rose 22% during mid-day trading on Friday . The company traded as high as $0.74 and last traded at $0.72. Approximately 125,477 shares changed hands during mid-day trading, an increase of 309% from the average daily volume of 30,690 shares. The stock had previously closed at $0.59.

Matinas Biopharma Price Performance

The company has a market cap of $4.62 million, a PE ratio of -0.21 and a beta of 1.28. The firm has a 50-day simple moving average of $0.73 and a two-hundred day simple moving average of $1.24.

Matinas Biopharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.